Donanemab approved to treat Alzheimer's disease

The TGA has approved a drug — donanemab — to treat Alzheimer's disease in its early stages. 

The drug has a small effect in slowing cognitive decline, however it isn't a cure and can have significant side effects. 

Also, the World Health Assembly adopts historic Pandemic Agreement with zero objections.